Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | GLA | P06280 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 6/20 | 0.59 |
| ▸ | RAB9A | P51151 | 5/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | FLT3 | P36888 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | NQO2 | P16083 | 1/20 | 0.57 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.53 |
| ▸ | ACACA | Q13085 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29386544 | 0.94 | SMN1; SMN2 (0.68) | SMN1; SMN2ALDH1A1MAPTGLAGAA | |
| SCHEMBL28456689 | 0.83 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1MAPTGLAGAA | |
| SCHEMBL28450186 | 0.83 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1MAPTGLAGAA | |
| SCHEMBL710433 | 0.82 | NPC1 (0.71) | SMN1; SMN2ALDH1A1MAPTGLAGAA | |
| SCHEMBL595944 | 0.81 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1MAPTGLAGAA | |
| SCHEMBL29351353 | 0.81 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1MAPTGLAGAA | |
| SCHEMBL28165865 | 0.80 | MAPT (0.61) | SMN1; SMN2ALDH1A1MAPTGLAGAA | |
| SCHEMBL28860564 | 0.80 | MAPK1 (0.54) | SMN1; SMN2ALDH1A1MAPTGLAGAA | |
| Hydrochloric Acid SCHEMBL8500142 | 0.79 | SMN1; SMN2 (0.97) | SMN1; SMN2ALDH1A1MAPTGLAGAA | |
| SCHEMBL9939451 | 0.79 | HPGD (0.64) | MAPTMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108043442-B | Carbon-supported ruthenium nano material, preparation method thereof and application of carbon-supported ruthenium nano material in catalyzing reaction of alcohol and aromatic diamine | 苏州大学 | 2021-03-19 | — | — | CN | disclosed |
| CN-102924458-B | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARM INC | 2014-11-05 | — | — | CN | disclosed |
| US-8735405-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-05-27 | — | — | US | disclosed |
| US-8653268-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130190496-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2013-07-25 | — | — | US | disclosed |
| CN-102924458-A | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARM INC | 2013-02-13 | — | — | CN | disclosed |
| US-8367826-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120196847-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2012-08-02 | — | — | US | disclosed |
| US-20120077979-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2012-03-29 | — | — | US | disclosed |
| US-7964399-B2 | Nucleotide sequence vector that encodes a truncated Flk-1 protein which inhibits the binding of VEGF; uses for evaluate and screen of cancer drugs; as biodrug for modulating vasculogenesis and angiogenesis, inhibiting the tumor growth | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-06-21 | — | — | US | disclosed |
| US-7964399-B2 | Nucleotide sequence vector that encodes a truncated Flk-1 protein which inhibits the binding of VEGF; uses for evaluate and screen of cancer drugs; as biodrug for modulating vasculogenesis and angiogenesis, inhibiting the tumor growth | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-06-21 | — | — | US | disclosed |
| CN-1960993-A | 6, 6-bicyclic substituted heterobicyclic protein kinase inhibitors | OSI PHARM INC (US) | 2007-05-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077979-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | SMN1; SMN2 2622/4885ALDH1A1 3941/4885MAPT 1546/4885 |
| US-20130190496-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | SMN1; SMN2 2622/4885ALDH1A1 3941/4885MAPT 1546/4885 |
| US-20120196847-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | SMN1; SMN2 2622/4885ALDH1A1 3941/4885MAPT 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.